Navigation Links
FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
Date:10/1/2009

ne hematin method. In the study, Mirena (n=79) was compared to an approved first-line hormonal therapy, medroxyprogesterone acetate (n=81), over six menstrual cycles. Successful treatment was defined when two outcomes were met: 1) a proportion of subjects with end-of-study MBL < 80 mL and 2) a greater than or equal to 50% decrease in MBL from baseline to end-of-study. Mirena demonstrated a significantly superior reduction in MBL. Additionally, a greater number of women in the Mirena arm achieved successful treatment vs. those in the medroxyprogesterone acetate arm (85% vs. 22%: respectively, p=<0.001). The study excluded women with organic or systemic conditions that may cause heavy uterine bleeding (except fibroids, with total volume not > 5 mL). The most common reported adverse events for Mirena in the study were uterine bleeding/spotting at irregular intervals, headache, ovarian cysts, vaginitis, pain during menstruation (dysmenorrhea), pelvic pain, and breast tenderness.

About Mirena

Mirena (levonorgestrel-releasing intrauterine system) is a removable intrauterine contraceptive that delivers small amounts of hormone directly to the uterus. It is among the most efficacious forms of birth control and works for up to five years. Mirena received FDA approval for the prevention of pregnancy in December 2000. It is currently used by approximately two million women in the U.S. and has been used by more than 15 million women worldwide.(3)

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals operation of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the United States, Bayer HealthCare Pharmaceuticals comp
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
2. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
3. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
4. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
5. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
6. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
7. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
8. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
9. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
10. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
11. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164335/Cardiac-Pacemakers---A-World-Market-Analysis.html , Pacemaker devices ... devices market. The worldwide cardiac pacemakers market is characterized ...
... , , PALO ALTO, Calif., Dec. ... November 25, 2009, Varian, Inc. filed with the U.S. Securities and ... year ended October 2, 2009. This Annual Report may be ... "Investors" and "SEC Filings," and then on "10-K" in the table ...
Cached Medicine Technology:Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... Cesar A. Arias, M.D., Ph.D., at The University of ... a new superbug that caused a bloodstream infection in ... 17 issue of The New England Journal of ... a class of highly-resistant bacteria known as methicillin-resistant ... cause of hospital and community-associated infections. The superbug has ...
(Date:4/17/2014)... than 40 years away from a food shortage that ... to a top scientist at the U.S. Agency for ... food production will be limited on a global scale ... Dr. Fred Davies, senior science advisor for the agency,s ... politically destabilizing by 2050 as energy issues are today.", ...
(Date:4/17/2014)... treatment that lost its status as the leading weapon ... lease of life, with new research indicating it simply ... revive the use of the cheap anti-malarial drug chloroquine ... the lives of more than half a million people ... causes malaria has developed resistance to chloroquine, but research ...
(Date:4/16/2014)... 2014) A team that includes scientists from the School ... at San Antonio, Johns Hopkins University and St. Mary,s University ... fungus to infect the body. , The fungal pathogen ... thrush, and is the most common fungal pathogen to infect ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2
... its employees further strengthen community support by donating an ... giving campaign DUBLIN, Ohio, Feb. 18 The Cardinal ... $1.2 million to non-profit programs that seek to improve ... Cardinal Health has the highest concentration of employees. Over ...
... (Nasdaq: ALGN ) today announced that the Company ... against the Company on February 17, 2009 by ClearCorrect, Inc. ... of Texas. Align Technology became aware of the filing on ... copy of the Complaint.In the Complaint, assigned case # H-09-470 ...
... Who Use the OmniPod System to Manage their Diabetes , ... country,s top professional cross-country skiers, is competing on behalf of ... As a world-class athlete, Freeman intends to medal, but he ... Diabetes doesn,t keep Freeman from performing at the top ...
... from this trial supported entry into Company,s current ... -,BELLEVILLE, ON, Feb. 18 /PRNewswire-FirstCall/ - Bioniche Life ... biopharmaceutical company, today announced that The Journal of ... II clinical trial results for the Company,s proprietary ...
... Calif., Feb. 18 In a dramatic move ... direct care RN organizations, the,United American Nurses, California ... Association today announced,they are joining together to form ... The new organization will be called the ...
... of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box solution for resellers ... ... -- SherWeb , a global leader in hosted solutions ... last week. The newly implemented program provides IT solution providers with ...
Cached Medicine News:Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 2Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 3Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 4Health News:Cardinal Health Foundation Invests $1.2 Million in Local Non-Profit Programs That Improve Health in Key Employee Communities 5Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Elite Skier Uses OmniPod(R) Insulin Management System at World Championships 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: